These include BRI2, which is related to familial British and Danish dementia (FBD and FDD); Chondromodulin-I, related to chondrosarcoma; CA11, related to stomach cancer; and surfactant protein C (SP-C), related to respiratory distress syndrome (RDS).
One derivative of it, compound name IPI-926, is currently undergoing clinical trials for the treatment of various types of cancer, including hard-to-treat hematologic malignancies, chondrosarcoma, and pancreatic cancer.